Clinical Trial Update: Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD) [Phase 1]

View source ↗

Summary

Phase I trial of brentuximab vedotin for refractory chronic graft-versus-host disease has been terminated; the study was conducted at Massachusetts General Hosp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Adcetris (Brentuximab vedotin)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Graft-vs-Host Disease, GVHD | Phase 1 | Status: TERMINATED